Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
353 studies found for:    PD-1
Show Display Options
Rank Status Study
21 Recruiting Sequential Intranodal Immunotherapy (SIIT) Combined With Anti-PD1 (Pembrolizumab) in Follicular Lymphoma
Condition: Follicular Lymphoma
Interventions: Radiation: Radiotherapy;   Biological: Rituximab;   Biological: Autologous dendritic cells;   Biological: GM-CSF;   Biological: Pembrolizumab
22 Completed Safety Study of IL-21/Anti-PD-1 Combination in the Treatment of Solid Tumors
Condition: Neoplasms by Site
Interventions: Biological: Denenicokin;   Biological: Nivolumab
23 Active, not recruiting Multiple Class I Peptides & Montanide ISA 51 VG w Escalating Doses of Anti-PD-1 ab BMS936558
Condition: Melanoma (Skin)
Interventions: Biological: MART-1;   Biological: NY-ESO-1;   Biological: gp100:209-217(210M);   Biological: gp100:280-288(288V);   Drug: Montanide ISA 51 VG;   Biological: BMS-936558
24 Recruiting Anti-PD-1 (MK-3475) and IMiD (Pomalidomide) Combination Immunotherapy in Relapsed/Refractory Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: MK-3475;   Drug: Pomalidomide;   Drug: Dexamethasone
25 Recruiting Pilot Study of Vigil™ + Pembrolizumab for Advanced Melanoma
Conditions: Melanoma Recurrent;   Malignant Melanoma;   Melanoma
Interventions: Biological: Vigil;   Drug: Pembrolizumab
26 Recruiting A Phase II Trial of Stereotactic Body Radiotherapy With Concurrent Anti-PD1 Treatment in Metastatic Melanoma.
Condition: Melanoma
Intervention: Radiation: stereotactic body radiotherapy
27 Not yet recruiting The Study to Evaluate JS001 in Patients With Advanced GC, ESCC, NPC, HNSCC
Conditions: Gastric Adenocarcinoma;   Esophageal Squamous Cell Carcinoma;   Nasopharyngeal Carcinoma;   Head and Neck Squamous Cell Carcinoma
Interventions: Biological: 3 mg/kg humanized anti-PD-1 mAb;   Biological: 10 mg/kg humanized anti-PD-1 mAb
28 Not yet recruiting Interest of Anti-telomerase T CD4 Immune Responses for Predicting the Effectiveness of Immunotherapies Targeting PD1 / PDL1
Condition: Cancer
Interventions: Other: Biological samples;   Drug: Anti PD1/PDL1 treatment
29 Recruiting Safety Study of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors
Condition: Neoplasms by Site
Interventions: Biological: BMS-986016;   Biological: BMS-936558
30 Completed PD-1/PD-L1 Pathway Study on Septic Patients
Condition: Sepsis
31 Enrolling by invitation Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of an Anti-PD-1 mAb for Patients With Advanced Solid Tumors
Conditions: Lymphoma;   Lung Cancer
Intervention: Biological: JS-001
32 Recruiting Ipilimumab vs Ipilimumab Plus Nivolumab in Patients With Stage III-IV Melanoma Who Have Progressed or Relapsed on PD-1 Inhibitor Therapy
Condition: Melanoma
Interventions: Drug: ipilimumab;   Drug: nivolumab
33 Recruiting A Study of Anti-PD-1 (Pembrolizumab) Therapy in Metastatic Melanoma (ADAPTeM)
Condition: Advanced Melanoma
Intervention: Drug: Pembrolizumab
34 Recruiting Pilot Study of Stereotactic Ablation for Oligometastatic Breast Neoplasia in Combination With the Anti-PD-1 Antibody MK-3475
Conditions: Breast Neoplasms;   Bone Neoplasms
Interventions: Radiation: Stereotactic Ablative Body Radiosurgery (SABR);   Drug: MK-3475
35 Active, not recruiting A Study Of 4-1BB Agonist PF-05082566 Plus PD-1 Inhibitor MK-3475 In Patients With Solid Tumors (B1641003/KEYNOTE-0036)
Condition: Advanced Solid Tumors
Interventions: Drug: PF-05082566;   Drug: MK-3475
36 Not yet recruiting Study of FAK (Defactinib) and PD-1 (Pembrolizumab) Inhibition in Advanced Solid Malignancies (FAK-PD1)
Conditions: Carcinoma, Non-small-cell Lung;   Mesothelioma;   Pancreatic Neoplasms
Interventions: Drug: Defactinib;   Drug: Pembrolizumab
37 Active, not recruiting AMP-224, a PD-1 Inhibitor, in Combination With Stereotactic Body Radiation Therapy in People With Metastatic Colorectal Cancer
Conditions: Colorectal Cancer;   Colorectal Neoplasms;   Colorectal Carcinoma
Interventions: Drug: AMP-224;   Radiation: Stereotactic Body Radiation Therapy(SBRT);   Drug: Cyclophosphamide
38 Recruiting E7 TCR T Cells With or Without PD-1 Blockade for Human Papillomavirus-Associated Cancers
Conditions: Cervical Cancer;   Vaginal Cancer;   Anal Cancer;   Penile Cancer;   Oropharyngeal Cancer
Interventions: Biological: E7 TCR cells;   Drug: pembrolizumab;   Drug: aldesleukin;   Drug: fludarabine;   Drug: cyclophosphamide
39 Active, not recruiting A Comparison of Continuous Bevacizumab (Avastin) Treatment or Placebo in Addition to Lomustine Followed by Standard of Care After Disease Progression in Participants With Glioblastoma
Condition: Glioblastoma
Interventions: Drug: Bevacizumab;   Drug: Lomustine;   Drug: Placebo;   Radiation: Radiotherapy;   Drug: SOC;   Drug: Temozolomide
40 Recruiting Phase II Study of Pembrolizumab and Ipilimumab Following Initial Anti-PD1/L1 Antibody
Condition: Melanoma
Intervention: Drug: Pembrolizumab and Ipilimumab combination

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years